IRLAB Therapeutics AB (publ) reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was SEK 59.56 million compared to SEK 29.17 million a year ago. Basic loss per share from continuing operations was SEK 1.15 compared to SEK 0.56 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.2 SEK | -0.98% | -6.17% | +102.67% |
05-27 | Sweden’s IRLAB Therapeutics Names New CEO | MT |
05-27 | IRLAB Therapeutics AB Announces CEO Changes, Effective from August 1, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+102.67% | 76.43M | |
+42.69% | 748B | |
+34.11% | 598B | |
-6.66% | 356B | |
+18.34% | 325B | |
+4.12% | 283B | |
+17.02% | 245B | |
+9.26% | 211B | |
-4.21% | 209B | |
+1.53% | 166B |
- Stock Market
- Equities
- IRLAB A Stock
- News IRLAB Therapeutics AB
- IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023